Researchers found that a new medication called Foundayo (orforglipron) may significantly improve health outcomes for people with type 2 diabetes and obesity. In a large clinical trial, Foundayo demonstrated a 16% lower risk of major cardiovascular events compared to the standard treatment, insulin glargine. More notably, it showed a remarkable 57% reduction in the risk of all-cause death, indicating potential benefits beyond just blood sugar control.

This is important for anyone looking to age well and maintain their health. With over 11,000 participants in the study, the results suggest that Foundayo could help reduce serious health risks associated with diabetes, such as heart disease and stroke. By improving key cardiovascular risk factors like cholesterol and blood pressure, Foundayo may offer a pathway to better overall health and longevity for those struggling with diabetes and weight management.

The evidence comes from the ACHIEVE-4 trial, which is part of a larger Phase 3 clinical program. While the findings are promising, they are still in the early stages of evaluation. The study involved a diverse group of participants, but more long-term research is needed to fully understand the medication’s effects and safety profile. As of now, Foundayo has shown consistent results across multiple studies, but it has not yet received regulatory approval specifically for diabetes treatment.

If you’re considering options for managing diabetes or weight, it’s essential to discuss with your healthcare provider whether Foundayo might be suitable for you, especially given its potential benefits and the need for a comprehensive approach that includes diet and exercise.

Source: investor.lilly.com